eoadjuvant FOLFIRINOX

Phase 2

Recruiting

• Conditions: Pancreatic cancer; Pancreatic cancer, Neoadjuvant therapy

• Registration Number: JPRN-jRCT1041220027
• Lead Sponsor: Yamashita Tatsuya

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-06-04
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Pathologically diagnosed as pancreatic adenocarcinoma or adenosquamous carcinoma; diagnosed as resectable or borderline resectable (BR-PV) (cohort1) or borderline resectable (BR-A); 20-80 years or older; ECOG Performance status 0 or 1; preservation of major organ function; written informed consent

Exclusion Criteria

double cancer; severe infection; refractory ascites or pleural effusion; pregnant or lactating women, or women of childbearing potential; metastases to central nervous system; mental disorder; severe complication; patients who investigator regards as inappropriate for candidate

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
R0 resection rate

Secondary Outcome Measures

Name	Time	Method
resection rate, pathological response, adverse event, completion rate, relative dose intensity, progression-free survival, 2-year survival, overall survival, subsequent therapy